News

Fierce Biotech1h
Amgen rolls out ph. 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Applied Clinical Trials Online1h
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...
Ozempic and Mounjaro have new competitor as trial sees people lose 20% of bodyweight in one year
The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...
What’s Happening With Amgen Stock?
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
STAT21h
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Devdiscourse18h
Amgen Unveils MariTide's Mixed Mid-Stage Results Amid Market Concerns
Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...
New once-a-month drug could treat diabetes and obesity, scientists say
New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...